Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions
Catia Marzolini, Daniel R. Kuritzkes, Fiona Marra, Alison Boyle, Sara Gibbons, Charles Flexner, Anton Pozniak, Marta Boffito, Laura Waters, David Burger, David Back, Saye Khoo
Abstract
Nirmatrelvir–ritonavir (NMV/r) is now being used to treat high-risk patients with mild to moderate COVID-19. This article provides advice to clinicians regarding recognition of medications likely to interact with NMV/r and suggests approaches to managing such drug–drug interactions. An algorithm is provided to assist in decision making.
Topics & Concepts
MedicineIntensive care medicineMEDLINEHealth careDiseaseMedical emergencyClinical decision support systemFamily medicineMedical prescriptionDecision support systemPrimary careClinical trialContext (archaeology)Advice (programming)Precision medicineClinical decision makingComparative effectiveness researchDisease managementClinical PracticeKey (lock)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchComputational Drug Discovery Methods